Hidden danger: study probes blood clot risk in cancer patients with COVID-19

NCT ID NCT04616846

Completed Knowledge-focused Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study investigates how often cancer patients with COVID-19 develop dangerous blood clots (venous thromboembolism). Researchers will screen participants using ultrasound and blood tests to detect clots, whether or not they cause symptoms. The goal is to understand the true rate of clotting in this vulnerable group and help guide future prevention and treatment strategies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors identify which cancer patients with COVID-19 are at highest risk for dangerous blood clots, leading to better screening and prevention guidelines.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test any new therapy. The findings may not apply to all cancer patients or all COVID-19 variants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer COVID-19 neoplasm Thromboembolism venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19 NEOPLASMS MALIGNANT THROMBOEMBOLISM

Contacts and locations

Locations

CHPG

Monaco, 98000, Monaco
CHU Nice

Nice, Alpes-Maritimes, 06000, France
Centre Antoine Lacassagne

Nice, Alpes-Maritimes, 06189, France
Centre Azuréen de Cancérologie

Mougins, Alpes-Maritimes, 06250, France
Clinique Saint-Georges

Nice, Alpes-Maritimes, 06105, France
Clinique Saint-Jean

Cagnes-sur-Mer, Alpes-Maritimes, 06800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.